De Bruyn C, Delforge A, Bron D, Ley P, de Hemptinne D, Stryckmans P
Service de Médecine Interne et Laboratoire d'Investigation Clinique Henri Tagnon, Institut J. Bordet, Brussels, Belgium.
Stem Cells. 1994 Nov;12(6):616-25. doi: 10.1002/stem.5530120609.
We evaluated the growth of cord blood myeloid progenitors or colony forming units granulocyte-macrophage (CFU-GM) and their response to various recombinant growth factors or colony stimulating factors (CSFs): interleukin 3 (IL-3), IL-6, granulocyte-macrophage CSF (GM-CSF) and stem cell factor (SCF). Using classical stimulant (human placenta conditioned medium or HPCM), we observed a significantly higher day-14/day-7 CFU-GM ratio in CB than in bone marrow (BM). The association of IL-3, IL-6, GM-CSF and SCF induced significantly more CB day-14 CFU-GM than HPCM. This effect is significantly greater in CB than in bone marrow. Since fetal calf serum (FCS) is known to contain inhibitors, we have compared the ability of CSFs to induce CFU-GM formation in FCS-supplemented and FCS-free culture. In CB, using HPCM, we obtained significantly more CFU-GM in FCS-free medium than in FCS-supplemented medium. This difference was corrected by the addition of anti-transforming growth factor-beta (TGF-beta) neutralizing antibody. However, with the association of the four CSFs, no significant difference between FCS and FCS-free culture was observed.
a) day-14/day-7 CFU-GM ratio was higher in CB than in BM indicating that CB CFU-GM are more primitive than BM CFU-GM; b) FCS can be successfully replaced by serum-free medium; c) FCS contains inhibitors of day-14 CFU-GM and among them TGF-beta; and d) the association IL-3, SCF, GM-CSF and IL-6 seems able to totally overcome the inhibitory effect of FCS.
我们评估了脐血髓系祖细胞或粒细胞-巨噬细胞集落形成单位(CFU-GM)的生长情况以及它们对各种重组生长因子或集落刺激因子(CSF)的反应:白细胞介素3(IL-3)、IL-6、粒细胞-巨噬细胞集落刺激因子(GM-CSF)和干细胞因子(SCF)。使用经典刺激物(人胎盘条件培养基或HPCM),我们观察到脐血中第14天/第7天的CFU-GM比值显著高于骨髓(BM)。IL-3、IL-6、GM-CSF和SCF联合使用诱导的脐血第14天CFU-GM比HPCM显著更多。这种效应在脐血中比在骨髓中显著更大。由于已知胎牛血清(FCS)含有抑制剂,我们比较了CSF在补充FCS和无FCS培养中诱导CFU-GM形成的能力。在脐血中,使用HPCM,我们在无FCS培养基中获得的CFU-GM比在补充FCS的培养基中显著更多。通过添加抗转化生长因子-β(TGF-β)中和抗体可纠正这种差异。然而,对于四种CSF联合使用,在FCS和无FCS培养之间未观察到显著差异。
a)脐血中第14天/第7天的CFU-GM比值高于骨髓,表明脐血CFU-GM比骨髓CFU-GM更原始;b)FCS可以成功地被无血清培养基替代;c)FCS含有第14天CFU-GM的抑制剂,其中包括TGF-β;d)IL-3、SCF、GM-CSF和IL-6联合使用似乎能够完全克服FCS的抑制作用。